Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations
- significantly mutated regions
- across cancer types
- functional molecular alterations
本文作者使用了21种肿瘤的4700多个肿瘤样本，以一种叫做基于密度聚类的方法（density-based clustering methods），尝试用空间聚类的方法将部分非编码区和编码区突变进行区间聚类，找到了许多肿瘤类型共有的以及特有的显著突变区间（SMRs），其中包括了许多非编码区和内含子区域的突变信息，并且分析了其与基因表达的关系，找到了一些与基因表达高度相关的SMRs。另外，作者特别强调了PIK3CA的突变，八种肿瘤中有6个SMRs都影响了PIK3CA.5和PIK3CA.6结构域，而PIK3CA.2和PIK3CA.3则是肿瘤类型特异的, 它影响了蛋白的adaptor-binding domain (ABD)和the linker region between the ABD and Ras-binding domain (RBD)。
In contrast, we observed cancer type–specific SMRs (PIK3CA.2 and PIK3CA.3) affecting an α-helical region between the adaptor-binding domain (ABD) and the linker region between the ABD and Ras-binding domain (RBD) of PIK3CA。
- inclusive of 将…包括在内
- density-based clustering methods
- variably sized significantly mutated regions (SMRs)
- a spectrum of 连续的，一连串的
- transcription factor binding sites and untranslated regions
- spatial clustering of alterations in molecular domains and at interfaces
- underscores 强调
- skewed 曲解的
- exon-proximal domains (±1,000 bp)
- reciprocal 相互的，互惠的
- leveraged 杠杆的
- elicit（引出） similar molecular profiles in distinct cancers
- interrogation 询问
- pleiotropy 基因多效性
- pathological variants
- functionally agnostic detection approaches
- elevated basal signaling activity
- replication timing and gene expression
- In cancer, driver mutations alter functional elements of diverse nature and size.
- Systematic analyses of genomic regulatory activity in animals have identified substantial tissue and developmental stage specificity, suggesting that mutations in cancer type–specific regulatory features may be significant noncoding drivers of cancer.
- SMRs were associated with noncoding elements, protein structures, molecular interfaces, and transcriptional and signaling profiles, thereby providing insight into the molecular consequences of accumulating somatic mutations in these regions.
- The identification of SMRs across multiple cancer types permitted a systematic analysis of differential mutation frequencies with subgenic and cancer type resolution.
- We next sought to identify SMRs that might affect the molecular interfaces of protein-protein and DNA-protein interactions, a recognized yet understudied mechanism of cancer driver mutation
- These findings underscore and extend recent associations between altered epigenetic regulation and histone alterations in tumorigenesis.
- We leveraged RNA sequencing (RNA-seq), RPPA and clinical data to ask whether (i) SMR alterations associate with distinct molecular signatures or survival outcomes, (ii) SMR alterations correlate with similar molecular profiles in distinct cancers, and (iii) SMR alterations in the same gene associate with similar or different molecular signatures.
- These analyses identified previously unappreciated connections between recurrent somatic mutations and molecular signatures, which highlight recurrent GSK3 pathway alterations in endometrial cancer and recurrent mTOR as well as EIF4 and epidermal growth factor (EGF) pathway alterations in glioblastoma
- The identified SMRs also permitted interrogation of mutations in different regions of a given gene with respect to associated molecular signatures.
- This functional diversity underscores both the varied mechanisms of oncogenic misregulation and the advantage of functionally agnostic detection approaches. Notably, several of the most frequently altered SMRs lay within noncoding regions.
- Mutation models that account for cell type–specific expression and chromatin context at refined scales may require sequencing cohorts of matched normal tissue and increased sample sizes.
- Identify the spatial distribution of mutation recurrence in the genome, when combined with additional genomic, biophysical, structural or phenotypic information, often enhances mechanistic insights.
~3 million previously identified somatic single-nucleotide variants (SNVs) from 4,735 tumors of 21 cancer types
5’ UTR 和启动子区的突变富集
six SMRs in PIK3CA across eight cancer types (Fig. 3b), with multiple cancer types displaying SMRs mapping to the helical (PIK3CA.5) and kinase (PIK3CA.6) domains.
In contrast, we observed cancer type–specific SMRs (PIK3CA.2 and PIK3CA.3) affecting an α-helical region between the adaptor-binding domain (ABD) and the linker region between the ABD and Ras-binding domain (RBD) of PIK3CA.
Matched RNA-seq data for nine cancers showed that mutations in 30 distinct SMRs associated with ≥10 differentially expressed genes.
NFE2L2 were associated with large, concordant transcriptomic changes in four distinct cancer types
SMR-specific differences in ASNS levels and MAPK and MEK1 phosphorylation among samples with altered TP53 SMRs.
Gini Coefficient 一般指基尼系数
Author Jianfeng Li
Markdown The Markdown version »